DCPXF (DanCann Pharma AS) Total Equity: $1.11 Mil (As of Sep. 2025)


DCPXF DanCann Pharma AS DCPXF
20 GF Score
Price $10.00
GF Value $37.14
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS Total Equity?

DanCann Pharma AS DCPXF 20 Total Equity is $1.11 Mil as of Sep. 2025. GuruFocus rates DCPXF with a GF Score™ of 20/100 and a GF Value™ of $37.14. The stock has 3 warning signs investors should review.

DanCann Pharma AS's total equity for the quarter that ended in Sep. 2025 was $1.11 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

DanCann Pharma AS Total Equity Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS Total Equity Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial 7.25 8.11 8.94 1.39 2.05

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 2.05 1.78 1.36 1.11
DCPXF
20GF Score
DanCann Pharma AS DCPXF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

DanCann Pharma AS's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=2.341-0.288
=2.05

DanCann Pharma AS's Total Equity for the quarter that ended in Sep. 2025 is calculated as

Total Equity=Total Assets(Q: Sep. 2025 )-Total Liabilities(Q: Sep. 2025 )
=2.013-0.902
=1.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $1.11 Mil mean?
DanCann Pharma AS (DCPXF) has a Total Equity of $1.11 Mil as of Sep. 2025. The total amount of equity as record on a company's balance sheet. View historical data for DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Total Equity too high?
DanCann Pharma AS's current Total Equity is $1.11 Mil. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Total Equity compare to ZTS and UTHR?
DanCann Pharma AS's Total Equity of $1.11 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for DanCann Pharma AS and its competitors. DanCann Pharma AS's current Total Equity is $1.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Total Equity of $1.11 Mil. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Total Equity is $1.11 Mil. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Total Equity is $1.11 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (DCPXF) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.

Key valuation signals for DCPXF:

  • Total Equity: $1.11 Mil
  • GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score

Get the complete analysis for DCPXF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$37.14
GF Value